Tag Archives: education

Registration Now Open for RESI JPM 2027 

7 Jul

By Max Braht, VP of Business Development, LSN

Max-Braht-Headshot

Life Science Nation is excited to announce that registration is now open for RESI JPM 2027, taking place January 11–12 at the San Francisco Marriott Marquis, followed by three days of virtual partnering on January 13, 18, and 19. 

Held alongside the world’s largest gathering of healthcare investors, executives, and innovators during JPM Week, RESI JPM provides early-stage life science companies with a unique opportunity to raise capital, build strategic partnerships, and accelerate business development in one of the industry’s most active networking environments. 

Previous RESI JPM conferences welcomed more than 1,000 attendees, including over 600 active investors, strategic partners, pharmaceutical business development professionals, and industry leaders. The conference combines curated educational programming with one-on-one partnering meetings, creating meaningful opportunities for fundraising companies to connect directly with the investors and partners best aligned with their technologies. 

The expanded format begins with two full days of in-person programming at the San Francisco Marriott Marquis, featuring investor panels, educational workshops, the Innovator’s Pitch Challenge, networking events, poster presentations, and partnering meetings. The conference then continues online with three additional days of virtual partnering, allowing participants to maximize the number of meetings they can schedule while extending networking opportunities beyond the in-person event. 

Whether you are seeking Seed, Series A, or Series B financing, exploring strategic partnerships, licensing opportunities, or looking to expand your visibility within the life science investment community, RESI JPM offers multiple ways to engage. Registration options are available for startups, fundraising executives, service providers, technology hubs, exhibitors, and qualified investors. 

Early Bird registration is now available, offering substantial savings on five-day hybrid registration for startups and fundraising executives. Register early to lock in the lowest available rates. 

Organizations looking to maximize their visibility during JPM Week can also take advantage of sponsorship and exhibition opportunities designed to connect brands with a highly targeted audience of investors, innovators, and industry leaders. 

Register today and save up to $900 with Super Early Bird pricing!

Register Now

Don’t miss your opportunity to be part of one of the life science industry’s premier fundraising and partnering events. 

Tags: , , , , , , , , , , , , , , ,

Accelerate Your Fundraising with Life Science Nation’s BD Assist 

7 Jul

By Sougato Das, President and COO, LSN

Sougato-Das

Raising capital is rarely about finding more investors. It’s about finding the right investors, telling the right story, and consistently building relationships that lead to meaningful opportunities. Additionally and importantly, it is about having a dedicated resource that finds those investors, reaches out to them regularly, and secures meetings with them.

Life Science Nation’s BD Assist program was created to help early-stage life science companies do exactly that by making Life Science Nation into that dedicated resource.

BD Assist is LSN’s premier business development program, providing startups with an experienced team dedicated to advancing their fundraising and partnering efforts throughout the year. Designed for companies seeking investment, licensing opportunities, or strategic collaborations, the program combines targeted investor research, strategic messaging, personalized outreach, and ongoing business development support into one comprehensive solution.

Every engagement begins by refining the company’s investment narrative and marketing materials to ensure they clearly communicate the value of the technology, market opportunity, and growth strategy. From there, Life Science Nation identifies and prioritizes a highly targeted global audience of investors and strategic partners whose interests align with the company’s stage, therapeutic area, and business objectives.

With the strategy in place, LSN launches and manages a personalized outreach campaign on the company’s behalf, tracking every interaction through the client’s CRM platform. Outreach is continuously refined based on engagement, allowing companies to build momentum over time while maintaining visibility with investors and corporate partners actively seeking new opportunities.

Clients also benefit from regular strategy discussions, ongoing campaign optimization, and access to Life Science Nation’s extensive global investor ecosystem. For companies participating in RESI conferences, BD Assist extends that support by managing partnering activities and helping maximize high-value meeting opportunities throughout the event.

Unlike traditional consulting services that provide recommendations, BD Assist becomes an extension of your business development team. LSN handles the day-to-day execution so your leadership can remain focused on advancing the science, growing the business, and preparing for meaningful investor conversations.

Whether you are preparing for your first institutional raise, expanding into new markets, or pursuing strategic partnerships, BD Assist provides the expertise, infrastructure, and execution to help accelerate your fundraising journey.

If your goal is to spend less time searching for investors and more time building relationships with the right ones, BD Assist was built for you.

Ready to activate your global roadshow? Click here to fill out the LSN Labs company assessment report and we’ll be in touch with you soon.

Click Here to Fill Out the LSN Labs Company Assessment Report

Tags: , , , , , , , , , , , , , , , , , , , , , ,

RESI San Diego Innovator’s Pitch Challenge Winners Showcase the Future of Life Science Innovation

30 Jun

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

The Innovator’s Pitch Challenge (IPC) returned to RESI San Diego 2026, bringing together some of the most promising early-stage life science companies for one of the conference’s signature events. Designed to connect early-stage innovators with active investors and strategic partners, the IPC provides a platform for companies to showcase breakthrough technologies while gaining valuable exposure and feedback.

Each finalist delivered a six-minute presentation followed by a live Q&A with an investor judging panel. Throughout the conference, participants also met with investors during one-on-one partnering meetings and networking sessions, extending conversations well beyond the pitch stage.

The IPC winners are determined through a combination of investor judge evaluations and RESI Cash voting. Judges evaluate each company based on the strength of its technology, investment opportunity, presentation, and responses during Q&A, while attendees allocate RESI Cash to the companies they believe demonstrate the greatest investment potential. Together, these scores recognize companies that impressed both the judging panel and the broader RESI community.

Congratulations to the overall winners of the RESI San Diego 2026 Innovator’s Pitch Challenge: 

1st Place: Nanotrace

Nanotrace combined the best attributes of chemotherapy, nanoparticle delivery mechanisms, and the latest advancements in gene therapeutics to build a revolutionary oncology platform. Based on our team’s decades of research in these fields, and the maturation of nanomedicine, our product is a novel targeting platform which recognizes cancer cells by its very blueprint – gene expression. In part by using AI, that highly specific recognition is programmed to release a chemotherapeutic payload inside a cancer cell while leaving healthy cells unaffected. Our platform will transform how we treat not only cancer but a whole spectrum of genetic disorders. Nanotrace is founded by Dr. Will Briley, PhD Molecular Biology from Northwestern; Dr. Paul Weiss, renowned nanoscientist, distinguished UCLA professor, and a UC Presidential Chair; David Spector, an experienced founder and formerly of Sequoia Capital, Google, and MIT; and, Chief Medical Advisor, Dr. Krishna Komanduri, Department Chief & Head of Hematology & Oncology, UCSF.

2nd Place: Pinion Immunotherapeutics

Pinion Immunotherapeutics is a Maryland-based biotechnology company focused on developing novel immunotherapies for chronic viral infections and virus-driven cancers. Its proprietary AI-driven mRNA platform generates immunotherapies targeting HPV-related precancer, AML, EBV, and HSV, designed to activate CD8⁺ T cells while inducing virus-neutralizing antibodies to achieve durable immune control. Pinion operates as a lean, high-impact virtual company, deploying capital directly to science and clinical trials, not overhead. Our leadership team brings deep expertise across mRNA platform development, FDA regulatory strategy, clinical trial design, and immunology. Our programs target indications with large addressable populations, no curative standard of care, and high economic burden, where mRNA immunotherapy offers a genuine path to functional cure.

3rd Place: FELIQS

Feliqs is a clinical-stage ophthalmology company developing innovative therapies for retinal and corneal diseases with significant unmet medical needs. The company is advancing a diversified pipeline targeting conditions including retinopathy of prematurity (ROP), pterygium, and dry age-related macular degeneration (Dry AMD), addressing diseases that currently have limited or no effective treatment options. Leveraging novel mechanisms targeting oxidative stress, fibrosis, and angiogenesis, FELIQS is developing patient-friendly therapies designed to reduce dependence on invasive procedures while improving long-term visual outcomes. Through its innovative ophthalmology pipeline, FELIQS aims to preserve vision, prevent blindness, and improve quality of life for patients worldwide.

In addition to the overall winners, several companies earned the highest combined judge and RESI Cash scores within their individual pitch sessions. Congratulations to these outstanding innovators for delivering exceptional presentations and capturing investor interest throughout the competition.

3Helix Ad-Astra Allander-Biotechnologies
BOOST-Pharma Endeavor FELIQS
HEPHAISTOS Nanotrace Numiera
Pinion Rejuvenation Repair
Sebastian Wavegate

Every company that participated in the Innovator’s Pitch Challenge demonstrated the innovation, passion, and entrepreneurial spirit that continue to define the RESI community. Congratulations to all of this year’s participants.

Will Your Company Be Next?

Applications are now open for the RESI Boston Innovator’s Pitch Challenge, taking place during the expanded two-day, in-person RESI Boston conference this September during Biotech Week Boston.

The IPC is more than a pitch competition. It is an opportunity to present your company to active investors, receive expert feedback, gain additional visibility through poster presentations and partnering meetings, and compete for recognition among the global life science investment community.

Whether you’re preparing for your next financing round or looking to build strategic partnerships, the Innovator’s Pitch Challenge can help elevate your fundraising efforts.

Applications are now open. Apply today and take the stage at RESI Boston.

Apply to Pitch at RESI Boston

Tags: , , , , , , , , , , , , , , , , , , , ,

Investor Insights: What It Really Takes to Land a Life Science Investment

30 Jun

By Sougato Das, President and COO, LSN

Sougato-Das

Securing investment is rarely about delivering the perfect pitch. Successful fundraising is built on understanding how investors evaluate opportunities, developing meaningful relationships, and communicating a compelling value proposition that stands up to diligence.

On Thursday, July 9, at 12:00 PM ET, Life Science Nation will bring together an outstanding panel of active life science investors for an in-depth discussion on what it takes to raise capital in today’s investment environment. The webinar will feature George Voren, VP of Founder Strategy and Operations at Curie.Bio; Yaniv Sneor, Founder of Mid Atlantic Bio Angels; Anna Crespo Puig, Investment Analyst at AdBio Partners; and Ankita Das, Senior Venture Development Associate, Therapeutics, at NLC Health Ventures. Together, they represent a diverse range of investment perspectives spanning venture creation, angel investing, venture capital, and strategic venture development.

George Voren
George Voren
Curie.Bio		 Yaniv Sneor
Yaniv Sneor
Mid Atlantic Bio Angels
Anna Crespo Puig
Anna Crespo Puig
AdBio Partners		 Ankita Das
Ankita Das
NLC Health Ventures

Moderated by Life Science Nation, the conversation is designed to deliver actionable insights for entrepreneurs preparing to raise capital, whether they are beginning their fundraising journey or actively engaging investors.

As market conditions continue to evolve, founders are navigating an increasingly competitive fundraising landscape. This webinar will provide practical guidance on how investors are approaching new opportunities, what they expect to see in executive summaries and pitch decks, how entrepreneurs can secure productive investor meetings both inside and outside partnering conferences, and the common mistakes that can derail an otherwise promising opportunity. The panel will also discuss what founders should expect once discussions move beyond a confidentiality agreement and into deeper diligence.

Reserve your spot today and join Life Science Nation on July 9 at 12:00 PM ET for this timely discussion.

Sign Up for the Investor Webinar

Tags: , , , , , , , , , , , , , , , , , , , , , ,

Build Your Brand at the Expanded Two-Day RESI Boston

30 Jun

By Max Braht, VP of Business Development, LSN

Max-Braht-Headshot

Following the success of RESI San Diego, sponsorship opportunities are now available for RESI Boston, taking place September 22–23 during Biotech Week Boston. With two days of in-person programming, followed by three days of virtual partnering, RESI Boston offers even more opportunities to connect with the global life science investment community.

RESI San Diego welcomed an outstanding group of sponsors representing every corner of the life science ecosystem. Title Sponsors included Innopolis Jeonbuk Innovation Cluster, Biometas, and Korea Bio Innovation Center (KBIC). Gold Sponsors RSM and Medmarc shared their expertise through thought leadership and networking, while Silver Sponsors Biocytogen, Foley Hoag, and Polsinelli connected with innovators and investors throughout the conference. Additional support from Bronze Sponsors BSR Korea, JABI, Jeongup Si, Jeonbuk State, the Ministry of Science and ICT (Korea), Alithia Life Sciences, and Inertia further strengthened the event’s international reach.

Sponsoring RESI is more than displaying your logo. Sponsors gain visibility before, during, and after the conference through digital marketing, onsite branding, exhibit opportunities, educational programming, and access to RESI’s partnering platform. Whether your organization is looking to generate business leads, recruit new clients, showcase a regional innovation ecosystem, or establish thought leadership, RESI provides direct access to founders, investors, strategic partners, and service providers actively shaping the future of life sciences.

The expanded two-day in-person format at RESI Boston means more networking, more meetings, more educational sessions, and more opportunities for meaningful engagement than ever before. Combined with virtual partnering that continues after the event, sponsors benefit from sustained visibility and valuable follow-up opportunities well beyond the conference itself.

Ready to elevate your brand at RESI Boston? Explore the full range of sponsorship opportunities by downloading the RESI Sponsorship Brochure, or visit the RESI Sponsors page to learn more. To discuss a customized sponsorship package that aligns with your business development goals, contact sales@lifesciencenation.com. Sponsorship packages can be tailored to maximize your visibility, thought leadership, and connections within the global life science investment community.

Tags: , , , , , , , , , , , , ,

Building Investor Readiness: Watch the First Two Sessions and Join the Final Webinar 

16 Jun

By Sougato Das, President and COO, LSN

Sougato-Das

As RESI San Diego approaches, Life Science Nation has been helping founders and executives prepare for investor conversations through a three-part webinar series focused on one of the most important challenges in life science fundraising: transforming strong science into a compelling investment opportunity.

The first two sessions in the series explored why many promising companies struggle to attract capital despite strong technology and how founders can better communicate risk reduction, investment readiness, and strategic value to investors.

Webinar Recording: De-Risking, Shaping, and Micro-Investment

In this session, Rick Berenson, partner to Dennis Ford in the Anchor Node project and co-author of Dissecting Return and Risk: A Framework for Financing Life Science Startups, examined how investors evaluate risk across early-stage companies and why scientific promise alone is rarely enough to secure funding.

The discussion explored the role of micro-investment as an early filtering mechanism, the importance of systematically reducing risk across the development pathway, and how founders can shape scientific assets into investable opportunities capable of attracting institutional capital.

Webinar Recording: From Pitch Deck to De-Risk Deck

Dennis Ford, Founder and CEO of Life Science Nation, challenged the traditional approach to fundraising presentations by introducing the concept of the “de-risk deck.”

The webinar explored why investors focus on evidence of risk reduction rather than vision alone and why capital flows toward companies that clearly communicate scientific, regulatory, execution, and commercialization progress. Dennis also discussed investor targeting, outreach strategy, and the realities of navigating a successful life science fundraising campaign.

Final Webinar: Science to Signal

June 18, 2026 | 1:00 PM ET

The webinar series concludes this Thursday with Science to Signal, presented by Max Braht and Karen Deyo.

This session introduces the Science to Signal framework, a practical system designed to help life science startups translate scientific achievements into clear investment signals. Attendees will learn how the framework aligns development strategy with investor risk assessment, supports enterprise implementation within incubators and innovation programs, and helps founders better communicate progress to potential investors and partners.

Register for Science to Signal

Whether you are actively fundraising, preparing for partnering meetings, or refining your investment story, this webinar series provides practical frameworks for improving investor engagement and positioning your company for more productive capital formation discussions.

Register for RESI San Diego

Tags: , , , , , , , , , , , , , , , , , , , , , ,

Don’t Miss Out: Discover Cutting-Edge Japanese Innovations at RESI San Diego 2026

9 Jun

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

With RESI San Diego 2026 just two weeks away, taking place on Monday, June 22, at JULEP Venue San Diego, we are excited to showcase a strong cohort of innovative life science companies and technologies from Japan.

As Title Sponsor of RESI San Diego 2026, Kobe Biomedical Innovation Cluster (KBIC) is organizing 2 incredible afternoon sessions featuring promising innovations that are being developed in Japan. We welcome you all to join and learn more about what Japan’s life science ecosystem has to offer.

Space is limited, so we ask that you RSVP to confirm your attendance.

RSVP to Confirm Attendance

1:00 – 3:00pm | KBIC Session –– Japan Life Science Showcase ––

KBIC is Japan’s largest leading biomedical cluster, bringing together approximately 350 companies, medical institutions, and research organizations.

Within this ecosystem, many startups are actively advancing R&D activities and working diligently toward commercialization on a daily basis.

As part of this exciting network, KBIC will host pitches from eight startups that are particularly eager to engage with overseas investors and licensing partners, and that are well prepared for such international collaboration.

In addition, leading venture capital firms in Japan and the representative of Ministry of Economy, Trade and Industry will speak about the current investment landscape as well as their perspectives on the future of the Japanese startup ecosystem.

ANT5 CellFold
FELIQS HIUCHI-Pharma
Juntendo-University Radio-Nano
United-Immunity VCCT

3:00 – 4:00pm | Kyoto-iCAP Session –– Translating Kyoto Science into Global Ventures ––

Kyoto University Innovation Capital Co., Ltd. (Kyoto-iCAP) and Kyoto University will introduce Kyoto’s growing biotech innovation ecosystem and showcase emerging life science ventures developing transformative technologies in regenerative medicine, cell therapy, nephrology, pain treatment and radiopharmaceuticals. The session is designed to foster connections between global investors, strategic partners, and leading Kyoto University-originated startups.

BTB Therapeutics CiRA
Orizuru-therapeutics Rege-Nephro
Shinobi_Therapeutics

Featured Interview: Dr. Narumiya, President of FBRI, shares his insights about Kobe and KBIC’s strengths and their role in strengthening the life science ecosystem in Japan.

Dr. Shuh Narumiya, President of Foundation for Biomedical Research and Innovation at Kobe (FBRI)

What is Kobe? What is KBIC?

Kobe is a port city and is now emerging as a key hub for startup creation and accumulation in Japan, particularly in bioscience and medicine. At the center of this ecosystem is the Kobe Biomedical Innovation Cluster (KBIC). In KBIC, you can meet institutes with Japan’s cutting-edge research, distinguished hospitals, research institutes of international Pharmas and start-ups, thus KBIC serving you as a “gateway to Japanese science and innovation”.

What science and innovation were and are being created in KBIC?

Science and innovation covered in KBIC span from drug discovery, regenerative medicine, digital health, and medical instruments and devices to bio-manufacturing. KBIC holds a distinctive position in regenerative medicine and cell therapy. It has, for example, nurtured and developed application of iPS cell research, leading to transplantation of iPSC-derived retinal cells in 2014, the world’s first clinical application, and the world’s first regulatory approval of iPSC-derived cells for a Parkinson’s disease treatment in 2026.

What are other advantages of KBIC?

Kobe is a part of Kansai region, an area of most distinguished life science research in Japan. Collaboration within the Kansai region is another strength of KBIC. Particularly, through partnerships with Kyoto University Innovation Capital (iCAP), KBIC supports the creation and growth of university spin-outs, combining Kyoto University’s research excellence with Kobe’s commercialization capabilities and vice versa.

What are the current state and issues of start-ups in Japan?

Today, Japan’s startup ecosystem—especially in the bio and life sciences sectors—is more vibrant than ever, producing a wealth of internationally competitive research and innovation seeds. However, these achievements are not yet fully recognized overseas, and many promising discoveries are still struggling for support to translate into commercial success. Bridging this gap is one of KBIC’s core roles.

Japan’s startups are now shifting from a domestically focused model to global expansion. In this transition, building international connections is critical. KBIC serves as a practical gateway for this purpose, offering integrated support from R&D to commercialization, fundraising, and global market entry.

Tags: , , , , , , , , , , , , , , , , ,

← Older Entries